AMRA-MEDICAL
25.4.2024 13:51:35 CEST | Business Wire | Press release
AMRA Medical, a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms, in collaboration with Linköping University, is pleased to announce the completion of baseline enrollment for the innovative ACCESS-ESLD (A Rapid, Non-invasive, Clinical Surveillance for CachExia, Sarcopenia, Portal HypertenSion, and Hepatocellular Carcinoma in End-Stage Liver Disease) study. The nationally-comprised study population includes 150 liver cirrhosis patients aged 18 and up, with no liver transplant history or contraindications to performing an MRI examination, enrolled from one of three Swedish liver care clinics located in Linköping, Eksjö, or Jönköping. Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination and a whole-body MRI examination.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240425020008/en/
A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol (Photo: Business Wire)
ACCESS-ESLD will characterize body composition using AMRA’s proprietary MRI-based health informatics platform to assess muscle volume (MV) and muscle fat infiltration (MFI), as well as measures of portal blood flow, liver stiffness, and spleen volume. These measures will be used to identify and validate risk factors and biomarkers that indicate current disease severity and predict future liver-related clinical events in patients with liver cirrhosis. AMRA’s muscle volume (MV) and muscle fat infiltration (MFI) measures have previously been shown to independently predict all-cause mortality1 and comorbid vulnerability2 in patients with fatty liver disease.
The primary objective of the study will be to determine whether or not changes in patient MV and MFI, either individually or in combination, can predict onset of events related to end-stage liver disease. Additionally, the investigators hope to identify predictors of mortality, assess non-invasive markers for portal hypertension, and evaluate how muscle composition and combined body profile assessments impact diagnosis, physical function and quality of life in patients with liver disease. The full manuscript detailing the ACCESS-ESLD study design and objectives was recently published in the journal BMC Gastroenterology in late 2023.
An indication that poses a significant clinical burden and unmet need for patients and providers, liver cirrhosis was historically centered around treatment of complications after they present in patients. The study investigators hope that the findings of ACCESS-ESLD will continue the shift in management of liver disease towards employing more of a preemptive approach, by developing ways to monitor disease progression and severity while also identifying novel biomarkers to help predict comorbid diseases/complications in patients.
“In Sweden, there’s a noticeable rise in liver disease, a condition often shadowed by social stigma and left neglected.” says Mattias Ekstedt at the department of health, medicine and caring sciences (HMV) at Linköping University. “The ACCESS-ESLD study promises to enhance our capabilities in detecting and tracking the progress of individuals living with liver disease, offering hope for better understanding and management of this health challenge.”
AMRA’s significant involvement in a hallmark study in the liver disease space such as this one embodies the company’s commitment to advancing both research and clinical care. Learn more about AMRA Medical and how the use of MRI-based body composition analysis is advancing disease research in liver disease and beyond.
References
1. Linge J, Nasr P, Sanyal A.J, Leinhard O.D, Ekstedt M, Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD, JHEP Reports, 2022: 5(3); 100663. https://doi.org/10.1016/j.jhepr.2022.100663
2. Linge J, Ekstedt M, Leinhard O.D, Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Reports, 2021: 3(1);100197. https://doi.org/10.1016/j.jhepr.2020.100197
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425020008/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OKX Launches X-Perps on the Magnificent 7 Stocks, Gold, Silver and Oil for European Traders9.6.2026 13:06:00 CEST | Press release
First MiFID-licensed platform to offer European retail traders 24/7 futures exposure to US stocks, commodities and the world's biggest* indices alongside crypto, on one accountSpaceX X-Perps to be available following IPO on June 12 OKX, a leading global fintech company and crypto trading platform, today launched 13 new X-Perp markets for traders across Europe, giving retail users direct access to futures on the "Magnificent 7" tech stocks, four major commodities and the world's biggest* indices. From today, OKX customers in Europe can trade futures on Apple, Amazon, Alphabet, Meta, Microsoft, Nvidia and Tesla, alongside Gold, Silver, WTI Crude Oil and Brent Crude Oil. SPY and QQQ X-Perps are also available, allowing Europeans to build wealth by offering price exposure to the 500 largest US companies and the 100 largest non-financial Nasdaq companies respectively. On Friday June 12, following its IPO, X-Perps on SpaceX will also become available. All markets are available 24/7, with up
Promega Receives SBTi Validation for Near-Term Science-Based Emissions Reduction Targets9.6.2026 13:01:00 CEST | Press release
Validated targets cover Scope 1, 2 and 3 emissions, including a supplier engagement commitment reaching 67% of suppliers by spend by 2030 Promega Corporation has received approval from the Science Based Targets initiative for its near-term emissions reduction targets, developed to reflect the current status of climate science. SBTi is a corporate climate organization that develops standards, tools and guidance for setting greenhouse gas emissions reductions targets in line with what is needed to avoid the worst impacts of climate change. “These goals aren’t just a commitment, they represent a verified plan with third-party accountability built in,” says Corey Meek, Corporate Responsibility Program Manager at Promega. “Our SBTi-validated targets reflect a comprehensive understanding of our greenhouse gas emissions across our entire value chain and set a clear, science-aligned standard for what we aim to achieve by 2030.” The Science Based Targets initiative has approved the following ne
IFF’s 2025 Do More Good Report Highlights Progress in Nature-Based Innovation9.6.2026 13:00:00 CEST | Press release
Driving growth for high-performance, sustainable solutions, while enabling customers to avoid 27.2 million metric tons of CO₂e emissions IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — released its 2025 Do More Good Report, highlighting the company’s commitment to creating better products and experiences for people and the planet. IFF’s increasingly nature-based portfolio underscores the central role of sustainability and positions its innovation at the intersection of biology and chemistry. Through continued investment in R&D, expanded global innovation partnerships and measurable impact across the value chain, the report demonstrates how IFF is reducing environmental impact while delivering differentiated performance and long-term value for customers and consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608586967/en/ Cover image for IFF’s 2025 Do More Good re
Icon Solutions Showcases How Banks Can Accelerate Digital Asset Innovation with IPF9.6.2026 11:30:00 CEST | Press release
Banks can now deploy digital asset payments faster, without risking fragmentation Icon Solutions – the UK fintech enabling banks to design and implement state-of-the-art payment systems – has released a reference implementation showing how banks can use the Icon Payments Framework (IPF) to accelerate support for payments processing using distributed ledger technology (DLT)-based digital assets. As IPF is agnostic to both the type of digital asset and the DLT network on which they are issued, the risk of fragmentation is reduced as adoption scales. There is growing momentum for digital assets such as stablecoins, tokenised deposits, deposit tokens and central bank digital currencies (CBDCs) to enable faster, cheaper and smarter payments. Yet the emergence of different digital asset types and DLT networks – which must also work with existing financial infrastructure – creates fragmentation and operational complexity for banks. This is compounded by legacy vendor solutions that limit choi
monday.com Appoints Ben Barnett General Manager of EMEA to Drive Next Phase of Regional Growth9.6.2026 10:00:00 CEST | Press release
In 2025, monday.com saw 26% YoY revenue growth in EMEABarnett will be a driving force in monday.com’s biggest transformation yet monday.com (Nasdaq: MNDY), the AI work platform that turns strategy into execution at scale, today announced Ben Barnett’s appointment to General Manager (GM) of Europe, the Middle East and Africa, marking a major milestone in the company’s global expansion. Ben, who has been with monday.com for five years, brings a decade of experience in senior B2B sales roles at software companies and has overseen significant, sustained growth at monday.com in the UK and Ireland since joining in 2021. In his new position, Ben’s priorities include delivering the monday.com’s EMEA go-to-market strategy, fostering key partnerships, and bolstering its newly announced AI work platform. He is based in London. Ben’s promotion comes as monday.com builds on a period of rapid regional success, with EMEA revenue up 26% year-on-year in 2025. Last year, monday.com expanded its regional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom